Skip to main content
SONOSCAPE MEDICAL CORP. logo

SONOSCAPE MEDICAL CORP. — Investor Relations & Filings

Ticker · 300633 ISIN · CNE100002P91 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2025-09-23 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300633

About SONOSCAPE MEDICAL CORP.

https://www.sonoscape.com

SonoScape Medical Corp. specializes in the research, development, and manufacturing of advanced medical diagnostic equipment. The company's primary product portfolio includes high-definition ultrasound systems, flexible endoscopy solutions, and electrocardiography devices. SonoScape focuses on delivering innovative imaging technology to healthcare providers globally, ranging from portable diagnostic tools to comprehensive trolley-based systems. Their ultrasound range covers various clinical applications such as cardiology, obstetrics, and radiology, while their endoscopy division provides high-resolution video processors and scopes for gastrointestinal and respiratory procedures. The company emphasizes continuous technological advancement and clinical efficiency to improve patient outcomes and diagnostic accuracy in diverse medical settings.

Recent filings

Filing Released Lang Actions
北京市中伦（深圳）律师事务所关于公司2025年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance qualifications, and voting results of the 2025 first extraordinary shareholders' meeting of Shenzhen Kaili Biomedical Technology Co., Ltd. It details the legal compliance of the meeting's notice, convening, attendance, and voting process, including the approval of several shareholder proposals. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholders' meeting process and outcomes. It is not a simple announcement or notice but a formal legal opinion letter. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official results and legal validation of shareholder votes at a general meeting.
2025-09-23 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary general meeting (临时股东大会) of Shenzhen Kaili Biomedical Technology Co., Ltd. It includes information about the meeting's convening, attendance, voting results on multiple proposals, and legal opinions confirming the legality and validity of the meeting and its resolutions. The document does not contain financial statements or management discussion and analysis but focuses on the voting results and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4137 characters, which is sufficient to include detailed voting results rather than a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2025-09-23 Chinese
监事会关于公司2025年限制性股票与股票期权激励计划激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Shenzhen Kaili Biomedical Technology Co., Ltd. regarding the verification and public disclosure of the list of incentive recipients under the company's 2025 restricted stock and stock option incentive plan. It includes details about the public notice, verification process, and compliance with relevant laws and regulations. The document does not contain financial statements, earnings data, or detailed financial analysis. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or legal proceeding update. It is a regulatory announcement related to the company's stock incentive plan and compliance verification. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-09-16 Chinese
董事会薪酬与考核委员会关于公司2025年限制性股票与股票期权激励计划激励对象名单的核查意见及公示情况说明
Remuneration Information Classification · 95% confidence The document is an announcement from the Board's Remuneration and Assessment Committee regarding the verification of the list of incentive recipients under the company's 2025 restricted stock and stock option incentive plan. It discusses compliance with relevant laws and regulations, the verification process, and confirms the eligibility of the incentive recipients. The content focuses on remuneration and incentive plans for executives and employees, which aligns with compensation-related disclosures. The document is not a full report but an announcement related to executive compensation and incentive plans, fitting the Remuneration Information category.
2025-09-16 Chinese
关于召开2025年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting (临时股东大会) of Shenzhen Kaili Biomedical Technology Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data or report content, but rather a formal announcement and instructions related to a shareholders' meeting. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document is not a report itself but a notice and procedural guide for the meeting.
2025-09-05 Chinese
董事会薪酬与考核委员会关于公司2025年限制性股票与股票期权激励计划相关事项的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the company's 2025 restricted stock and stock option incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and the plan's alignment with shareholder interests. There is no financial data or report content, but rather a committee's verification and approval statement about the incentive plan. This fits the Remuneration Information category, which covers reports detailing compensation and incentive plans for executives and directors. The document length is short and focused on remuneration matters, not a full report or announcement of a report publication.
2025-09-05 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.